Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YZD-27
- Development stage
- Unknown
- Lead developer
- Xi'an Qinshen Jiahe Pharmaceutical Research
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
YZD-27 is a chemical drug under development as an injectable formulation, currently in Phase 1 clinical trials. It is being investigated primarily for the treatment of acute ischemic stroke, with additional potential applications in nervous system and cardiovascular diseases. The drug's mechanism of action has not been publicly disclosed as of June 2025. The first-in-human studies are focused on evaluating its safety, tolerability, pharmacokinetics, and metabolic characteristics in healthy subjects. YZD-27 was developed by Xi'an Qinshen Jiahe Pharmaceutical Research Co., Ltd., which remains the active organization behind its clinical development[1].
Beyond the preview
Go deeper on YZD-27.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YZD-27.